CoMFA 3D-QSAR Analysis of HIV-1 RT Nonnucleoside Inhibitors, TIBO Derivatives Based on Docking Conformation and Alignment
暂无分享,去创建一个
[1] Ajay N. Jain. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.
[2] R. Pauwels,et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2. , 1991, Journal of medicinal chemistry.
[3] Pierre L'Ecuyer,et al. Implementing a random number package with splitting facilities , 1991, TOMS.
[4] Marcela Madrid,et al. Docking of non‐nucleoside inhibitors: Neotripterifordin and its derivatives to HIV‐1 reverse transcriptase , 2002, Proteins.
[5] Prashant V Desai,et al. Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies , 2003, Protein science : a publication of the Protein Society.
[6] S. Hannongbua,et al. Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis. , 2000, Journal of molecular graphics & modelling.
[7] Jarmo Huuskonen. QSAR Modeling with the Electrotopological State: TIBO Derivatives , 2001, J. Chem. Inf. Comput. Sci..
[8] R. Zauhar,et al. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. , 2000, Journal of medicinal chemistry.
[9] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[10] E. Pedersen,et al. Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom , 1999, Antiviral chemistry & chemotherapy.
[11] Supa Hannongbua,et al. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors , 1999, J. Comput. Aided Mol. Des..
[12] Bernard R Brooks,et al. A core-weighted fitting method for docking atomic structures into low-resolution maps: application to cryo-electron microscopy. , 2003, Journal of structural biology.
[13] M L Lamb,et al. Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. , 2000, Protein engineering.
[14] Li Wang,et al. Hierarchy of protein assembly at the vertex ring domain for yeast vacuole docking and fusion , 2003, The Journal of cell biology.
[15] E. Clercq,et al. Antiviral therapy for human immunodeficiency virus infections. , 1995 .
[16] A. D. Clark,et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.
[17] Xiaomin Luo,et al. Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A. , 2002, Journal of Medicinal Chemistry.
[18] S. Hughes,et al. Retroviral reverse transcription and integration: progress and problems. , 1992, Annual review of cell biology.
[19] Roger J.-B. Wets,et al. Minimization by Random Search Techniques , 1981, Math. Oper. Res..
[20] E. Arnold,et al. HIV reverse transcriptase structure-function relationships. , 1991, Biochemistry.
[21] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[22] D. Richman,et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.
[23] M. Miranda,et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3. , 1991, Journal of medicinal chemistry.
[24] J. Buolamwini,et al. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.
[25] Stanislav Miertus,et al. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties. , 2002, Journal of medicinal chemistry.
[26] S. Goff,et al. Retroviral reverse transcriptase: synthesis, structure, and function. , 1990, Journal of acquired immune deficiency syndromes.
[27] M L Lamb,et al. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.
[28] Erik De Clercq,et al. Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues , 1999 .
[29] Michael Wiese,et al. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4- dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: A molecular modeling study , 1999, J. Comput. Aided Mol. Des..
[30] D. Stuart,et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.
[31] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[32] Jianping Ding,et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.
[33] Ingo Muegge,et al. 3D-Quantitative Structure Activity Relationships of Biphenyl Carboxylic Acid MMP-3 Inhibitors: Exploring Automated Docking as Alignment Method , 2001 .
[34] J N Weinstein,et al. Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. , 1995, Journal of medicinal chemistry.
[35] A. Debnath,et al. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. , 1999, Journal of medicinal chemistry.
[36] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[37] A. Debnath,et al. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. , 1994, Journal of medicinal chemistry.
[38] U. Singh,et al. A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .
[39] C. Dominguez,et al. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.
[40] Atul Purohit,et al. Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. , 2003, Bioorganic & medicinal chemistry letters.
[41] K. Andries,et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo benzodiazepin-2(1H)-one (TIBO) derivatives , 1991 .
[42] M J Kukla,et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4. , 1995, Journal of medicinal chemistry.
[43] Jared Spidel,et al. Kinetic and docking studies of the interaction of quinones with the quinone reductase active site. , 2003, Biochemistry.
[44] Opera Ti,et al. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. , 1994 .
[45] C. Hansch,et al. Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .
[46] G Klebe,et al. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.
[47] A. Carotti,et al. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). , 1999, Bioorganic & medicinal chemistry.
[48] R. Pauwels,et al. Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives. , 1991, Journal of medicinal chemistry.
[49] J L Sullivan,et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. , 1991, The Journal of infectious diseases.
[50] Ricardo L. Mancera,et al. A new quantum stochastic tunnelling optimisation method for protein–ligand docking , 2003 .
[51] Margaret A. Johnson,et al. A novel modeling protocol for protein receptors guided by bound-ligand conformation. , 2003, Biochemistry.
[52] D I Stuart,et al. Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. , 1999, Journal of medicinal chemistry.
[53] Jianping Ding,et al. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. , 1996, Drug design and discovery.
[54] L. Loeb,et al. Human Immunodeficiency Virus Reverse Transcriptase , 1996, The Journal of Biological Chemistry.